Immunocore (NASDAQ:IMCR) Insider David Berman Sells 22,532 Shares

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) insider David Berman sold 22,532 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunocore Stock Performance

IMCR stock opened at $33.42 on Friday. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $23.15 and a 1-year high of $39.33. The company has a debt-to-equity ratio of 1.01, a current ratio of 5.89 and a quick ratio of 5.86. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -83.55 and a beta of 0.77. The business has a 50 day simple moving average of $33.98 and a two-hundred day simple moving average of $31.88.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.The business had revenue of $130.65 million during the quarter, compared to the consensus estimate of $122.96 million. During the same period in the prior year, the company posted ($0.23) EPS. The firm’s revenue for the quarter was up 30.0% compared to the same quarter last year. Research analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Institutional Trading of Immunocore

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Oppenheimer Asset Management Inc. purchased a new stake in Immunocore during the 1st quarter valued at $225,000. GAMMA Investing LLC raised its holdings in Immunocore by 3,318.1% during the 1st quarter. GAMMA Investing LLC now owns 19,107 shares of the company’s stock valued at $5,670,000 after buying an additional 18,548 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in Immunocore by 5.2% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company’s stock valued at $209,228,000 after buying an additional 351,610 shares during the period. Banque Transatlantique SA purchased a new stake in Immunocore during the 1st quarter valued at $278,000. Finally, Checkpoint Capital L.P. purchased a new stake in Immunocore in the first quarter worth $267,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IMCR shares. Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 4th. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Deutsche Bank Aktiengesellschaft started coverage on Immunocore in a research report on Tuesday, May 27th. They set a “buy” rating and a $65.00 target price for the company. Guggenheim started coverage on Immunocore in a research report on Thursday. They set a “neutral” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, June 2nd. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $56.89.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.